A glioblastoma diagnosis comes fast. You feel pressure to act immediately - from doctors, family, and fear. Pausing for a second review might feel risky. It's not. For a disease this complex and rare, a second opinion is a smart clinical move. For many patients, it changes their treatment plan in real ways.
Do you need a second opinion for glioblastoma?
Most neuro-oncology specialists say yes. Glioblastoma is complex and relatively rare. Most community oncologists and general cancer centers see only a small number of cases per year. Both the diagnosis and the treatment plan benefit from review by an expert neuropathologist and neuro-oncologist. A second opinion can confirm your diagnosis, refine your molecular markers, and find clinical trial options or treatment strategies your current team might not have mentioned. It rarely delays treatment by more than a week or two.
Why GBM makes a second opinion especially important
Glioblastoma is not a common cancer. Most community oncologists and general cancer centers see a small number of cases per year. Good care needs specific expertise - in neuropathology, surgical technique, radiation planning, and staying current with new research.
The 2021 WHO classification of central nervous system tumors changed how glioblastoma is defined. Now it's based on molecular markers as well as how cells appear under a microscope. Whether the tumor carries an IDH (isocitrate dehydrogenase) mutation determines the actual diagnosis. IDH-wildtype and IDH-mutant tumors are biologically different diseases. They have different outcomes and require different treatment plans. MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation shows whether the tumor has silenced a specific DNA repair gene. This is the best predictor of how well temozolomide, the standard chemotherapy for GBM, will work.
Research in the International Journal of Molecular Sciences shows that molecular profiling predicts outcomes better than how much tumor doctors remove. The extent of surgery is itself an important prognostic factor. Getting the molecular profile right at diagnosis shapes every decision that follows. If your initial pathology came from a center without neuropathology expertise, an independent review might find something that changes your diagnosis or treatment plan.
The National Brain Tumor Society says that a second opinion after a brain tumor diagnosis makes sense. The society recommends review at a high-volume or academic institution with a dedicated neuropathologist and a neuro-oncology division.
Five moments that call for a second opinion
1. Right after diagnosis, before surgery
This is the best time to get a second opinion. Surgery is usually the first major step, and the surgical plan affects what can safely be removed. Different surgical techniques exist - fluorescence-guided resection using 5-ALA dye, intraoperative MRI, awake craniotomy for tumors near speech or motor areas. Not every center or surgeon uses all of them. The National Brain Tumor Society recommends getting a second opinion before brain surgery. A misdiagnosis can lead to the wrong treatment plan from the start.
Many comprehensive cancer centers can review imaging in one to two weeks - often before your surgery is scheduled. You don't need to delay urgent surgery. You should confirm your surgical team and approach are right before the first cut is made.
2. When the molecular pathology is incomplete
After tissue is removed, the pathology report should include IDH status, MGMT methylation status, TERT promoter mutation status, and 1p/19q codeletion where relevant. If any key marker is listed as 'not done,' 'indeterminate,' or simply missing, have it tested before treatment starts. The American Brain Tumor Association's guide for newly diagnosed patients emphasizes this: a specialist who knows the current WHO classification should confirm your diagnosis. An incomplete molecular workup is not a minor detail - everything in your treatment plan depends on it.
3. Before starting the Stupp protocol
The Stupp protocol - daily temozolomide with radiation at the same time, followed by additional temozolomide cycles - is the standard first-line treatment for most GBM patients with good performance status. But the protocol isn't applied the same way at every center. Radiation planning, dose schedule, whether Tumor Treating Fields (TTFields, electrical patches worn on the scalp during chemoradiation) are used, and whether trial add-ons are available all vary between centers. A second opinion before chemoradiation begins can confirm the protocol is complete and follows the guidelines. It can also identify clinical trials you qualify for before you start treatment and lose trial eligibility.
For a step-by-step look at the protocol, The Stupp Protocol for Glioblastoma, Phase by Phase breaks down each stage and the questions to ask at each point.
4. When your options feel limited
If your current team gave you only one option without mentioning clinical trials, off-label drugs, or advanced procedures, a second opinion at a dedicated brain tumor center makes sense. This isn't about distrust. Community oncologists treat many cancers across many disease sites. Neuro-oncology specialists at academic centers focus on brain tumors full time. They're much more likely to know which clinical trials are open at ClinicalTrials.gov for your specific molecular profile. The gap between what a general center offers and what a specialist center knows can be real.
5. At recurrence
When GBM returns, there's no single standard approach. The right choice depends on where and how the tumor came back, how long since your first treatment, your neurological function, and what molecular findings - possibly from a repeat biopsy - are driving the new growth. The NCI's guide to questions to ask at recurrence covers re-irradiation, bevacizumab, surgical options, and clinical trial eligibility in practical detail.
A second neuro-oncology opinion at this stage can find options that weren't available at first diagnosis - including laser ablation, re-irradiation, or trials that need specific molecular criteria you now have. If you're planning your next steps after recurrence, Glioblastoma Recurrence: Building Your Second Opinion Case covers how to approach that process systematically.
What a GBM second opinion actually covers
A second opinion is more than a basic review. At a quality center, it's a structured clinical assessment that typically includes:
- Independent neuropathology review of the original tissue slides, classified using WHO 2021 criteria
- Confirmation or revision of molecular markers - IDH, MGMT, EGFR, CDKN2A/B deletion, and others relevant to your specific case
- Radiological review of all MRI sequences, including preoperative, postoperative, and any surveillance imaging
- Assessment of surgical completeness and whether additional resection might be appropriate
- A treatment recommendation specific to your molecular profile, age, and performance status
- Review of open clinical trials and the eligibility criteria you meet
Many leading cancer centers now offer remote second opinions. You send tissue slides and digital imaging. The reviewing team provides a written report, usually within one to two weeks. You don't need to travel. The ABTA's description of the tumor board process explains how a multidisciplinary panel - neurosurgeon, neuro-oncologist, radiation oncologist, and neuropathologist - reviews cases at high-volume centers. If your current hospital doesn't have a dedicated brain tumor board, that's a good reason to seek review at a center that does.
For families navigating this from abroad, or from a region without a specialist neuro-oncology center nearby, a remote clinical review is the best practical first step. You can arrange a remote second opinion through Art of Healing Cancer, which coordinates specialist neuro-oncology review of imaging and pathology for international patients and families.
Will a second opinion delay treatment?
This concern stops most families from seeking a second review. For newly diagnosed patients, the short answer is: not significantly. Between surgery and the start of chemoradiation, most patients have a recovery and planning window of three to six weeks. Most remote second opinions finish within that window.
In urgent situations - rapidly worsening symptoms or high intracranial pressure - many centers can speed up their review. Even then, taking a few extra days to confirm everything is rarely what determines the outcome. What matters more than speed is accuracy. Starting with the wrong plan is harder to fix than taking time to get it right from the start.
What to do when two opinions conflict
It happens. Two experienced neuro-oncologists sometimes recommend different approaches. This reflects real uncertainty in a disease where there aren't many large studies and individual variation is high. It's not a system failure.
When opinions differ, ask each provider:
- What evidence supports your recommendation compared to the other approach?
- What are the realistic risks if I choose the other path?
- Would you be willing to discuss this case with the other team, or present it at a multidisciplinary tumor board?
A third opinion from a different institution can sometimes clarify things. So can asking both centers to specify exactly what they would do differently and why, rather than just repeating their recommendation. Bring someone who can take notes and ask follow-up questions without the pressure of the moment. If you're gathering your records for any of these reviews, How to Prepare for a Glioblastoma Second Opinion covers exactly what to gather, how to request your tissue block, and how to send imaging securely.
When to talk to your doctor
Talk to your current oncologist about how to request your tissue block or slides for transfer, whether your insurance covers a second-opinion consultation, and whether the timing of a review fits your treatment window. Most physicians welcome input from another doctor - many will help coordinate the process and can recommend appropriate centers. If you encounter resistance, remember that you have the right to access your own medical records and to seek independent review at any point in your care, without asking permission.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.